N
Nucleus Genomics
Offers an all-in-one DNA health test, combining whole-genome sequencing with lifestyle factors to deliver the comprehensive insights into health and well-being
About Nucleus Genomics
Nucleus Genomics provides DNA testing and analysis services. The company offers an all-in-one DNA test that provides insights into a person's genetic makeup.
One of the company's key offerings is Nucleus Embryo, a genetic optimization software designed to assist parents undergoing in-vitro fertilization (IVF). This software helps in the selection of embryos with the most desirable genetic traits.
In addition to its consumer-facing products, Nucleus Genomics also provides a free gene variant discovery tool called GenVue Discovery. This tool is compatible with various data sources and allows users to explore their genetic data in more detail.
The company operates in the direct-to-consumer genetic testing market, serving individuals and couples who are interested in learning more about their genetic predispositions and, in the case of IVF patients, optimizing their chances of a successful pregnancy.
Nucleus Genomics places a strong emphasis on data privacy and security, as evidenced by its detailed privacy policy and HIPAA notice. The company is committed to protecting the personal and health information of its users.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- New York City, United States
- Employees
- 43
- Open positions
- None listed
- Dealroom signal
- 82.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Sequencing, Health Diagnostics, Genome Engineering, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jan 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2025 | $14M | $56M | Amanda Bradford · Asylum VC · Founders Fund · Neo vc | ↗ |
| SEED✓Equity / VC | Jul 2022 | $14M | $56M | Adrian Aoun · Packy McCormick · Founders Fund · Austen Allred | ↗ |
Growth signals
Latest recorded traffic for Nucleus Genomics is 99K monthly website visits, down 1% over the last three months. Nucleus Genomics's team grew 10.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Blueprint GeneticsUses Next Generation Sequencing (NGS) to perform diagnostics on genetic diseases |
Espoo, Finland | Operational | 220 | $36M | $62M |
 Nucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine |
Oxford, United Kingdom | Operational | |||
 AnnoroadA leading developer and marketer on genomic innovation technologies for research and clinical market |
Dongcheng District, China | Operational | |||
 BiomodalSimultaneous genetic and epigenetic sequencing from single samples |
Cambridge, United Kingdom | Operational | |||
 BGIDNA sequencing service provider part of BGI Group |
Shenzhen, China | Operational | |||
 Probably GeneticProbably Genetic helps rare genetic disease patients get diagnosed |
San Francisco, United States | Operational | |||
 GeneCast BiotechnologyIt is a Beijing cancer diagnosis company |
Haidian, China | Operational | |||
 23MofangGenetics testing and analyzing Startup Based In China |
Chengdu, China | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed23 investors entered at this stage
Edward Lando
Adrian Aoun
Quiet Capital- BWBrandon White
Adam Guild- NINight
Founders Fund
Ankur Nagpal
Joshua Browder
Shrug Capital
Pareto Holdings
SALT Fund- BSBrent Saunders
- BVBluewatch Ventures
Cory Levy
Matteo Franceschetti
Patrick Hsu
Packy McCormick
Austen Allred
Anthony Pompliano
Hugo Barra- ABAlexandra Botez
Seven Seven Six
Series A8 investors entered at this stage
- ABAmanda Bradford
Asylum VC
Neo vc
Rose Street Capital
Balaji Srinivasan- CMCommon Metal
Giant Step Capital- OCOne Eight Capital
Other known investors3 additional known investors
Entwistle
Night Ventures
Thiel Fellowship
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nucleus Genomics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nucleus Genomics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.